Effects of Anti-TNF-alpha Antibody Therapy on IVIG-resistant Patients with Kawasaki Disease

被引：0
|
作者：
Masuda, Hiroshi
Abe, Jun
Oana, Shinji
Ishiguro, Akira
Tsuchida, Nao
Sakai, Hirokazu
Ito, Shuichi
Ono, Hiroshi
Kato, Hitoshi
机构：
来源：
CIRCULATION | 2015年 / 131卷
关键词：
Kawasaki disease; Cardiovascular disease;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O.51
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects
    Pijls, Philippe A. R. R.
    Gilissen, Lennard P. L.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 (11) : 1391 - 1393
  • [42] Anti-TNF-alpha neutralizing activity of patients' sera evaluated with a novel interleukin (il)-8 reporter cell line correlates with the clinical response to anti-TNF-alpha antibody
    Kimura, Y.
    Omori, R. S.
    Takahashi, T.
    Tsuchiyama, K.
    Kusakari, Y.
    Yamasaki, K.
    Aiba, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 19 - 19
  • [43] EFFECTS OF PHYSICAL ACTIVITY AND ANTI-TNF-ALPHA DISEASE CONTROL ON LIPID PROFILE OF RHEUMATOID ARTHRITIS PATIENTS
    Cacciapaglia, F.
    Lervolino, S.
    Anelli, M. G.
    Mazzotta, D.
    Zincarelli, C.
    Pappone, N.
    Lannone, F.
    Lapadula, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1009 - 1009
  • [44] Certolizumab pegol - A pegylated anti-TNF-alpha antibody fragment for the treatment of Crohn's disease
    Schlesselman, Lauren S.
    FORMULARY, 2008, 43 (01) : 22 - 28
  • [45] Anti-TNF-alpha therapy and the risk of severe bacterial infections
    Schneeweiss, Sebastian
    Setoguchi, Soko
    Weinblatt, Michael E.
    Katz, Jeffrey N.
    Avorn, Jerry
    Sax, Paul E.
    Levin, Raia
    Solomon, Daniel H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S28 - S28
  • [46] Anti-TNF-alpha therapy for acute rejection in intestinal transplantation
    Pascher, A
    Klupp, J
    Langrehr, JM
    Neuhaus, P
    TRANSPLANTATION PROCEEDINGS, 2005, 37 (03) : 1635 - 1636
  • [47] Paradoxical cutaneous manifestations during anti-TNF-alpha therapy
    Viguier, M.
    Richette, P.
    Bachelez, H.
    Wendling, D.
    Aubin, F.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2010, 137 (01): : 64 - 71
  • [48] THE EFFECTS OF ANTI-TNF-ALPHA ANTIBODY AND DEXAMETHASONE ON TCDD-INDUCED OXIDATIVE STRESS IN MICE
    ALSHARIF, NZ
    HASSOUN, E
    BAGCHI, M
    LAWSON, T
    STOHS, SJ
    PHARMACOLOGY, 1994, 48 (02) : 127 - 136
  • [49] Immunomodulators provide no reduction in loss of response for inflammatory bowel disease patients starting anti-TNF-alpha therapy
    Varma, P.
    Yeaman, F.
    Holt, D.
    Moore, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 140 - 141
  • [50] EVALUATING ANTI-TNF-ALPHA THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY LANGERHANS CELL HISTIOCYTOSIS
    Burke, Thomas
    Legarreta, Alejandra
    Lin, Howard
    Scull, Brooks
    Eckstein, Olive
    McClain, Kenneth
    Allen, Carl
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S2 - S3
12345